Regeneron To Receive 42.75 Million From Novartis To Satisfy Novartis' Remaining Funding Obligation For Development Of The IL-1 T
Regeneron Also Achieves Development Milestone, Resulting In Loan Forgiveness
05-Apr-2004 -
Tarrytown, NY. Regeneron Pharmaceuticals, Inc. announced that Novartis Pharma AG has agreed to pay Regeneron $42.75 million to satisfy its obligation to fund development costs for the Interleukin-1 (IL-1) Trap for the nine month period following notification of Novartis' decision to forgo its ...
inflammation
inflammatory disease
Novartis
+1